Avacopan vs lower-dose steroids for new vasculitis

This trial tests if adding avacopan, a medication that helps calm the immune system, to usual treatment can improve kidney function in people with a type of blood vessel inflammation called vasculitis that affects the kidneys. It's for people with severe kidney involvement who are starting standard treatment.

This study tests a new combination treatment for people newly diagnosed with a type of kidney inflammation linked to ANCA-associated vasculitis. The treatment combines a targeted medication (obinutuzumab) with a low dose of steroids, aiming to control the disease with fewer side effects.

This study compares two ways of managing ANCA-associated vasculitis (inflammation of blood vessels) when ANCA antibodies reappear after remission. One approach is close monitoring with blood tests, and the other is giving rituximab infusions right away to prevent a flare-up. It aims to find out which strategy better prevents disease relapse.

This study brings together patients with ANCA-associated vasculitis (AAV) and their doctors to talk about how they make treatment decisions together. The goal is to understand what matters to patients so care can be more collaborative.

This trial tests a medication called avacopan for people with ANCA-associated vasculitis, a condition where the immune system attacks blood vessels. Avacopan is taken with standard treatments to help control the disease and may reduce the need for steroids.

This study looks at how well the drug avacopan works for people with a rare blood vessel disease called ANCA-associated vasculitis. It aims to help patients who are starting this treatment by tracking real-world results.